Trial Profile
Clinical Trial of the Efficacy, Dosing, Safety and Tolerability of Y- Shaped Pegylated Interferon (YPEG-IFNalpha-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Apr 2011 New trial record